Sign in

CIK 0001566044

  • Non-accelerated filer
  • Smaller reporting company

Yarrow Bioscience, Inc.

Sign in to watch
Ticker
YARW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
453757789
Phone
+1 203-433-7577
Business address
470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
Former names
VYNE Therapeutics Inc., Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 2 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2018-01-29 Remeditex Ventures LLC 10% owner Conversion · Series A Preferred Stock −7,150 0
2018-01-29 Remeditex Ventures LLC 10% owner Conversion · Series B Preferred Stock −2,351,097 0
2018-01-29 Remeditex Ventures LLC 10% owner Conversion · Series C Preferred Stock −821,596 0
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion +2,348,550 2,606,982
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion +324,306 359,992
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion +917,559 3,524,541
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion +126,703 486,695
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion · Series B Preferred Stock −6,335,215 0
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion · Series B Preferred Stock −874,817 0
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion · Series C Preferred Stock −2,475,118 0
2018-01-29 Vivo Capital VIII, LLC 10% owner Conversion · Series C Preferred Stock −341,784 0
2018-01-29 Cha Albert Director Conversion +2,348,550 2,606,982
2018-01-29 Cha Albert Director Conversion +324,306 359,992
2018-01-29 Cha Albert Director Conversion +917,559 3,524,541
2018-01-29 Cha Albert Director Conversion +126,703 486,695
2018-01-29 Cha Albert Director Conversion · Series B Preferred Stock −6,335,215 0
2018-01-29 Cha Albert Director Conversion · Series B Preferred Stock −874,817 0
2018-01-29 Cha Albert Director Conversion · Series C Preferred Stock −2,475,118 0
2018-01-29 Cha Albert Director Conversion · Series C Preferred Stock −341,784 0
2018-01-25 venBio Global Strategic Fund II L.P. 10% owner Purchase +265,000 $17.00 $4.5M 265,000

Page 21 of 22 · 425 trades